Vice Provost and Dean of Research
Showing 1,101-1,110 of 2,457 Results
-
Hyunjin Kim
Licensing Manager, Life Sciences, Office of Technology Licensing (OTL)
BioHyunjin is a Licensing Manager at Stanford Office of Technology Licensing. Hyunjin holds a PhD in Biochemistry from the University of Illinois at Chicago. With a strong foundation in life sciences, Hyunjin joined Aspire Capital as a biotech analyst intern where she gained valuable experience in analyzing and assessing biotech companies with clinical stage assets. After the internship, Hyunjin joined the Office of Technology Management at University of Illinois at Chicago where she managed various intellectual properties. At Stanford, Hyunjin is responsible for managing life science portfolios.
-
Juyong Brian Kim
Assistant Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsThe lifetime risk of developing cardiovascular disease (CVD) is determined by the genetic makeup and exposure to modifiable risk factors. The Cardiovascular Link to Environmental ActioN (CLEAN) Lab is interested in understanding how various environmental pollutants (eg. tobacco, e-cigarettes, air pollution and wildfire) interact with genes to affect the transcriptome, epigenome, and eventually disease phenotype of CVD. The current focus is to investigate how different toxic exposures can adversely remodel the vascular wall leading to increased cardiac events. We intersect human genomic discoveries with animal models of disease, in-vitro and in-vivo systems of exposure, single-cell sequencing technologies to solve these questions. Additionally, we collaborate with various members of the Stanford community to develop biomarkers that will aid with detection and prognosis of CVD. We are passionate about the need to reduce the environmental effects on health through strong advocacy and outreach.
(http://kimlab.stanford.edu) -
Peter S. Kim
Virginia and D. K. Ludwig Professor of Biochemistry
Current Research and Scholarly InterestsOur research focuses on developing new strategies for vaccine creation. We also aim to generate vaccines targeting infectious agents that have eluded efforts to date. We integrate experimental approaches with protein language models to guide artificial evolution and enable efficient antibody and protein engineering. Our interdisciplinary approach aims to address critical global health challenges.
-
Seung K. Kim M.D., Ph.D.
KM Mulberry Professor, Professor of Developmental Biology, of Medicine (Endocrinology) and, by courtesy, of Pediatrics (Endocrinology)
On Partial Leave from 09/16/2025 To 03/31/2026Current Research and Scholarly InterestsWe study the development of pancreatic islet cells using molecular, embryologic and genetic methods in several model systems, including mice, pigs, human pancreas, embryonic stem cells, and Drosophila. Our work suggests that critical factors required for islet development are also needed to maintain essential functions of the mature islet. These approaches have informed efforts to generate replacement islets from renewable sources for diabetes.
-
Sun Kim, M.D. M.S.
Associate Professor of Medicine (Endocrinology)
Current Research and Scholarly InterestsWe are interested in studying the pathophysiological processes that contribute to glucose intolerance and type 2 diabetes mellitus. My current research focuses on characterizing pancreatic beta-cell function in populations with significant insulin resistance and vulnerability to developing diabetes: individuals with schizophrenia, morbid obesity, and history of gestational diabetes.
-
Yong Yean Kim
Assistant Professor of Pediatrics ( Hematology & Oncology)
BioOur lab is interested in translational science to bring new therapies to clinical trials. In particular, we are interested in pediatric sarcomas which have not had advancement in clinical treatment for decades. Current projects in the lab focus on understanding of the biology of fusion transcription factor PAX3::FOXO1 which is the driver mutation in fusion positive rhabdomyosarcoma. PAX3::FOXO1 is a powerful oncogenic transcription factor which rewires the transcriptional organization to lock the cancer cell in the proliferative state. Since transcription factors including PAX3::FOXO1 are difficult to target using small molecules, we aim to understand how PAX3::FOXO1 is regulated and targeting the regulators of PAX3::FOXO1. By understanding and targeting the regulation of PAX3::FOXO1, we hope to bring new therapies for fusion positive rhabdomyosarcoma. Additionally, these regulatory mechanisms may also be active in other transcription driven cancers such as the EWSR1::FLI1 driven Ewings Sarcoma.
Our lab is also interested in exploring the epigenetic landscape of pediatric solid tumors and trying to understand how dysregulation in the epigenome drives oncogenesis. We utilize various CRISPR mediated genetic techniques to interrogate the regulators of epigenome focusing on the histone lysine demethylases (KDMs). KDMs are an understudied group of epigenetic regulators which can be targeted for therapeutic effect. We explore the role of KDMs in pediatric solid tumors and hope to identify potential targets for drug development.
